DS
NGNE icon

David Shaw’s Neurogene NGNE Stock Holding History

David Shaw’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$308K Buy
+9,781
New +$269K ﹤0.01% 4398
2026
Q1 		– Sell
-40,347
Closed -$831K – 4876
2025
Q4 		$831K Buy
+40,347
New +$1M ﹤0.01% 3650
2022
Q3 		– Sell
-9,821
Closed -$202K – 5410
2022
Q2 		$202K Buy
9,821
+1,215
+14% +$29.6K ﹤0.01% 4552
2022
Q1 		$324K Buy
8,606
+5,440
+172% +$317K ﹤0.01% 4612
2021
Q4 		$305K Buy
3,166
+1,858
+142% +$226K ﹤0.01% 4670
2021
Q3 		$189K Buy
+1,308
New +$200K ﹤0.01% 4583
2021
Q1 		– Sell
-857
Closed -$242K – 4337
2020
Q4 		$242K Buy
+857
New +$209K ﹤0.01% 3669
2020
Q3 		– Sell
-1,650
Closed -$548K – 4041
2020
Q2 		$548K Buy
1,650
+17
+1% +$4.43K ﹤0.01% 3304
2020
Q1 		$372K Sell
1,633
-2,943
-64% -$606K ﹤0.01% 3360
2019
Q4 		$1.13M Sell
4,576
-1,282
-22% -$128K ﹤0.01% 2897
2019
Q3 		$334K Sell
5,858
-460
-7% -$28.1K ﹤0.01% 3405
2019
Q2 		$298K Hold
6,318
– – ﹤0.01% 3316
2019
Q1 		$341K Sell
6,318
-8,914
-59% -$450K ﹤0.01% 3169
2018
Q4 		$658K Sell
15,232
-131
-0.9% -$6.38K ﹤0.01% 2932
2018
Q3 		$900K Buy
15,363
+13,936
+977% +$822K ﹤0.01% 2757
2018
Q2 		$76K Buy
1,427
+394
+38% +$103K ﹤0.01% 3632
2018
Q1 		$291K Buy
1,033
+104
+11% +$28.7K ﹤0.01% 3163
2017
Q4 		$218K Buy
929
+375
+68% +$87.9K ﹤0.01% 3399
2017
Q3 		$157K Buy
+554
New +$159K ﹤0.01% 3335

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

David Shaw's NGNE Position: Q2 2026 in Review

David Shaw opened a new position in Neurogene (NGNE) in Q2 2026: 9,781 shares worth $308K. The stake represents ﹤0.01% of the portfolio and ranks #4398 among its holdings. This is a return to the name: David Shaw previously reported a position in NGNE as recently as Q4 2025.

David Shaw first reported a position in NGNE in Q3 2017 and has held it in 19 quarters since. The position peaked at $1.13M in Q4 2019. 111 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • David Shaw held 9,781 shares of Neurogene worth $308K as of Q2 2026.
  • Neurogene was a new David Shaw position in Q2 2026.
  • Neurogene made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4398 holding.
  • David Shaw first reported a position in Neurogene in Q3 2017 and has held it in 19 quarters since.
  • David Shaw's Neurogene position peaked at $1.13M in Q4 2019.
  • 111 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.